PT  - JOURNAL ARTICLE
AU  - GIROLAMO DEL MONTE
AU  - PATRIZIA FERRONI
AU  - SABRINA MARIOTTI
AU  - EMANUELA FOSSILE
AU  - FIORELLA GUADAGNI
AU  - MARIO ROSELLI
TI  - Interleukin-2 Inhalation Therapy in Renal Cell Cancer: A Case Report and Review of the Literature
DP  - 2008 Jul 01
TA  - In Vivo
PG  - 481--488
VI  - 22
IP  - 4
4099  - http://iv.iiarjournals.org/content/22/4/481.short
4100  - http://iv.iiarjournals.org/content/22/4/481.full
SO  - In Vivo2008 Jul 01; 22
AB  - Renal cell carcinoma (RCC) is the most common malignancy of the kidney. One third of RCC presents metastatic disease at the time of diagnosis, usually leading to a fatal outcome. Small response rates were seen with most cytotoxic agents including gemcitabine and vinorelbine, whereas systemic therapy with high doses of interleukin 2 (IL-2) has been shown to provide durable complete remissions. However, in consideration of its severe toxicity, IL-2 immunotherapy is restricted to selected patients. Aerosol IL-2 has been introduced as an alternative therapy in cancer patients. However, only very few data are available on its use in patients with pulmonary metastatic RCC. This paper briefly summarizes current clinical experience with the use of inhaled IL-2 therapy, either as a single therapy or in combination with other treatments. In addition, we report on a male patient with pulmonary metastasized RCC who achieved a durable complete response to combined gemcitabine/vinorelbine and interleukin-2 inhalation therapy.